EDI THERAPEUTICS LLC

Biotech · Private

Recombinant fibronectin fragments (matrix mimetics) that promote wound healing by mimicking insoluble fibronectin fibrils

Grants
$662K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Fibronectin matrix mimetic, Chimectin as a first-in-class therapeutic for chronic wound healing$388,193
Federal grantDepartment of Health and Human Services · Phase I · Chimectin as a novel wound biologic for xylazine-induced tissue injury$274,219
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2700VOVA IDA THERAPEUTICS INC——
2701ZVELT THERAPEUTICS INC.——
2702DUB THERAPEUTICS INC.——
2703EDI THERAPEUTICS LLC——
2704OSEM FLUIDICS INC——
2705Capture Pharmaceuticals, Inc.——
2706Helicore Biopharma——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.